Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Mölndal, Sweden, December 1[st], 2022 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that NYU Langone Health has completed its first patient treatment using the OPRA[TM] Implant System, marking the initiation of NYU Langone's Center for Amputation Reconstruction's Osseointegration Program which will be added to the center's expertise in treatment of limb loss. Furthermore, OPRA[TM ]Implant System will be offered as part of an Osseointegration Program for Bone Cancer patients at the Perlmutter Cancer Center, a part of the NYU Langone Health Center.
NYU Langone is ranked among the top five hospitals in the US for orthopedic surgery, according to the U.S. News & World Report. The department employs more than 200 orthopedic physician faculty experts and performs approximately 23,000 procedures each year. In August 2022, Dr. Ayalon and Dr. Hacquebord, co-directors of the center, completed their initial surgical procedure of the center's first patient, using the OPRA[TM ]Implant System. The second surgery was performed in November 2022. Following the successful procedures, NYU Langone's Center for Amputation Reconstruction center now announces that Integrum's OPRA[TM] Implant will be offered to patients in the greater New York Area as part of the center's Osseointegration Treatment Program.
"The opportunity to provide this unique and comprehensive solution for our patients indicates a paradigm shift in the treatments we are able to offer individuals with limb loss and help improve their day-to-day lives. Osseointegration is a life-changing procedure, and we collaborate with our multidisciplinary team to tailor the treatment plan to each individual's needs and expectations," said Omri B. Ayalon, MD, orthopedic surgeon, and co-director of NYU Langone's Center for Amputation Reconstruction.
In December 2020, the OPRA[TM] Implant System received FDA approval for treatment in individuals who have undergone transfemoral, or above-knee, amputations, and who have, or are anticipated to have, rehabilitation problems with, or cannot use, a conventional socket prosthesis.
"We are very glad over the uptake of our unique implant system into one of the US' most prestigious healthcare centers. The success is twofold, as the uptake of our technology is not only a clear testament to the pristine quality of our system but also an acceleration toward broader use in individuals suffering from mobility challenges. We look forward to our future interactions with NYU Langone Health Center, aiding their work to transform the lives of eligible patients," comments Rickard Brånemark, CEO of Integrum.